<?xml version="1.0" encoding="UTF-8"?>
<p>Whether patients with these rare disorders are more susceptible to COVID-19 and its complications, or whether COVID-19 could precipitate tumor-related complications (infarct or necrosis) in these patients is unknown. Patients with glucagonoma may be at increased risk of severe COVID-19 because of hyperglycemia and a thrombophilic state [
 <xref rid="CIT0110" ref-type="bibr">110</xref>]. Patients on immunosuppressive therapies will also be vulnerable to COVID-19. Implications for management of these patients during the COVID-19 pandemic are reviewed elsewhere [
 <xref rid="CIT0111" ref-type="bibr">111</xref>].
</p>
